Last edition
News about "licensing agreement"
THX Pharma and Biocodex Sign Licensing Deal for Rare Disease Drug Candidates
Biocodex secures global rights to Batten-1 and North American rights to TX01 from THX Pharma in a deal worth up to Euro 173 million to advance treatments for juvenile Batten disease, Gaucher disease and Niemann-Pick type C.
Licensing Agreement | 13/02/2026 | By News Bureau
Genethon Partners with AskBio on Pompe Gene Therapy
The licensing deal enables AskBio to advance the clinical development of Genethon’s investigational gene therapy for Pompe disease through an industry partnership.
Licensing Agreement | 15/01/2026 | By News Bureau
Valneva and Serum Institute End Chikungunya Vaccine Licensing Deal
Valneva SE and the Serum Institute of India have mutually agreed to discontinue their licensing agreement for Valneva’s single-shot chikungunya vaccine, bringing the collaboration to a close by mutual consent.
Licensing Agreement | 01/01/2026 | By News Bureau
Biofabri and Bharat Biotech Sign Technology Transfer Deal for MTBVAC
Biofabri and Bharat Biotech have entered into a technology transfer agreement to enable end-to-end manufacturing of the MTBVAC tuberculosis vaccine candidate, supporting global efforts to expand access to new TB prevention options, particularly in high-burden, low- and middle-income countries.
Licensing Agreement | 24/12/2025 | By News Bureau | 109
Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma
Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.
Licensing Agreement | 17/12/2025 | By News Bureau
Actimed Therapeutics Announces Licensing Agreement with Mankind Pharma
Actimed Therapeutics has entered into an exclusive licensing agreement with Mankind Pharma for S-pindolol, its novel therapy in development for cancer cachexia. The partnership marks a step toward delivering the first globally approved treatment for this debilitating condition to patients across India and South Asia.
Licensing Agreement | 21/11/2025 | By Dineshwori | 106
Ocugen and Kwangdong Finalise OCU400 Gene Therapy Deal for Retinitis Pigmentosa in Korea
Pursuant to the licence agreement, Ocugen will receive upfront license fees and near-term development milestones equaling up to USD 7.5 million. The company will be entitled to sales milestones of USD 1.5 million for every USD 15 million of sales in Korea, projected to reach USD 180 million or more in the first 10 years of commercialisation.
Licensing Agreement | 17/09/2025 | By Dineshwori | 394
Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against the collaboration targets.
Licensing Agreement | 05/01/2024 | By Manvi | 531
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy